{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:29:45Z","timestamp":1791293385932,"version":"4.1.0"},"reference-count":178,"publisher":"Elsevier BV","issue":"20","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jacc.2025.08.100","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T18:39:55Z","timestamp":1762799995000},"page":"1861-1884","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["The Basics of Metabolic Dysfunction\u2013Associated Steatotic Liver Disease for Cardiologists"],"prefix":"10.1016","volume":"86","author":[{"given":"Muhammad Shahzeb","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Sarmad","family":"Javaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amreen","family":"Dinani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1024-9040","authenticated-orcid":false,"given":"Kara","family":"Wegermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambarish","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6449-4535","authenticated-orcid":false,"given":"Ankeet S.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Muthiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8370-4569","authenticated-orcid":false,"given":"Harriette G.C.","family":"Van Spall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-1570","authenticated-orcid":false,"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Volk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marat","family":"Fudim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2025.08.100_bib1","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","article-title":"Global incidence and prevalence of nonalcoholic fatty liver disease","volume":"29","author":"Teng","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jacc.2025.08.100_bib2","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.medj.2024.07.013","article-title":"Multisystem health comorbidity networks of metabolic dysfunction-associated steatotic liver disease","volume":"5","author":"Jiang","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.jacc.2025.08.100_bib3","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","article-title":"Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association","volume":"42","author":"Duell","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2025.08.100_bib4","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMra0912063","article-title":"Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease","volume":"363","author":"Targher","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.100_bib5","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.jacc.2015.06.1328","article-title":"The CardioMetabolic Health Alliance: working toward a new care model for the metabolic syndrome","volume":"66","author":"Sperling","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.08.100_bib6","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.08.100_bib7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3390\/biom15020213","article-title":"From cardiovascular-kidney-metabolic syndrome to cardiovascular-renal-hepatic-metabolic syndrome: proposing an expanded framework","volume":"15","author":"Theodorakis","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.jacc.2025.08.100_bib8","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1038\/s41591-024-03223-z","article-title":"Integrating liver endpoints in clinical trials of cardiovascular and kidney disease","volume":"30","author":"Zannad","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2025.08.100_bib9","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/s12933-024-02434-5","article-title":"Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review","volume":"23","author":"Zheng","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2025.08.100_bib10","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2025.08.100_bib11","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S2468-1253(24)00193-6","article-title":"Natural history and progression of metabolic dysfunction-associated steatotic liver disease","volume":"9","author":"Hagstr\u00f6m","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jacc.2025.08.100_bib12","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2025.08.100_bib13","doi-asserted-by":"crossref","DOI":"10.1097\/MCG.0000000000002202","article-title":"Prevalence of MASLD, Met-ALD, and ALD and associated fibrosis among US adults: insights from NHANES 2017 to 2023","author":"Paik","year":"2025","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jacc.2025.08.100_bib14","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/oby.20426","article-title":"Racial differences in nonalcoholic fatty liver disease in the U.S. population","volume":"22","author":"Schneider","year":"2014","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.jacc.2025.08.100_bib15","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1053\/j.gastro.2010.09.038","article-title":"Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study","volume":"140","author":"Williams","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jacc.2025.08.100_bib16","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1111\/j.1572-0241.2002.05795.x","article-title":"Is NASH underdiagnosed among African Americans?","volume":"97","author":"Caldwell","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jacc.2025.08.100_bib17","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s43856-024-00649-x","article-title":"Disparities in steatosis prevalence in the United States by Race or Ethnicity according to the 2023 criteria","volume":"4","author":"D\u00edaz","year":"2024","journal-title":"Commun Med (Lond)"},{"key":"10.1016\/j.jacc.2025.08.100_bib18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5005\/jp-journals-10018-1437","article-title":"Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in persons with obesity and type 2 diabetes mellitus: a cross-sectional study","volume":"14","author":"Latif","year":"2024","journal-title":"Euroasian J Hepatogastroenterol"},{"key":"10.1016\/j.jacc.2025.08.100_bib19","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1002\/hep4.1981","article-title":"Nonalcoholic fatty liver disease prevalence and severity in Asian Americans from the national health and nutrition examination surveys 2017-2018","volume":"6","author":"Truong","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jacc.2025.08.100_bib20","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3350\/cmh.2022.0239","article-title":"Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach","volume":"28","author":"Le","year":"2022","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jacc.2025.08.100_bib21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2025.08.100_bib22","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/joim.13035","article-title":"Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011-2016","volume":"287","author":"Le","year":"2020","journal-title":"J Intern Med"},{"key":"10.1016\/j.jacc.2025.08.100_bib23","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jhep.2025.03.001","article-title":"Cause-specific mortality in 13,099 patients with metabolic dysfunction-associated steatotic liver disease in Sweden","volume":"83","author":"Issa","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jacc.2025.08.100_bib24","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000386","article-title":"The future of International Classification of Diseases coding in steatotic liver disease: an expert panel Delphi consensus statement","volume":"8","author":"Hagstr\u00f6m","year":"2024","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jacc.2025.08.100_bib25","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2025.08.100_bib26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.7570\/jomes22021","article-title":"Recent epidemiology and risk factors of nonalcoholic fatty liver disease","volume":"31","author":"Huh","year":"2022","journal-title":"J Obes Metab Syndr"},{"key":"10.1016\/j.jacc.2025.08.100_bib27","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3350\/cmh.2023.0035","article-title":"Association of visceral fat obesity, sarcopenia, and myosteatosis with non-alcoholic fatty liver disease without obesity","volume":"29","author":"Kim","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jacc.2025.08.100_bib28","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1111\/liv.14852","article-title":"Sarcopenia in nonalcoholic fatty liver disease and all-cause and cause-specific mortality in the United States","volume":"41","author":"Kim","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jacc.2025.08.100_bib29","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2025.08.100_bib30","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.cgh.2022.12.025","article-title":"Association of HSD17B13 and PNPLA3 with liver enzymes and fibrosis in Hispanic\/Latino individuals of diverse genetic ancestries","volume":"21","author":"Rutledge","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jacc.2025.08.100_bib31","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacc.2025.08.100_bib32","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jacc.2018.11.050","article-title":"Nonalcoholic fatty liver disease and the heart: JACC State-of-the-Art Review","volume":"73","author":"Stahl","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.08.100_bib33","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwae306","article-title":"Cardiovascular disease and metabolic dysfunction-associated steatotic liver disease: pathophysiology and diagnostic aspects","author":"M\u00f8ller","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacc.2025.08.100_bib34","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s11892-024-01542-6","article-title":"Metabolic dysfunction-associated steatotic liver disease and atherosclerosis","volume":"24","author":"Castillo-N\u00fa\u00f1ez","year":"2024","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.jacc.2025.08.100_bib35","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/abbs\/gmv092","article-title":"Excess TNF-\u03b1 in the blood activates monocytes with the potential to directly form cholesteryl ester-laden cells","volume":"47","author":"Zhu","year":"2015","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"10.1016\/j.jacc.2025.08.100_bib36","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3390\/metabo14030153","article-title":"Interleukins: pathogenesis in non-alcoholic fatty liver disease","volume":"14","author":"Rafaqat","year":"2024","journal-title":"Metabolites"},{"key":"10.1016\/j.jacc.2025.08.100_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.880298","article-title":"Association of inflammatory cytokines with non-alcoholic fatty liver disease","volume":"13","author":"Duan","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jacc.2025.08.100_bib38","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.molimm.2022.04.003","article-title":"IL-6 regulates induction of C-reactive protein gene expression by activating STAT3 isoforms","volume":"146","author":"Ngwa","year":"2022","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jacc.2025.08.100_bib39","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.3390\/ijms22083850","article-title":"Endothelial dysfunction, inflammation and coronary artery disease: potential biomarkers and promising therapeutical approaches","volume":"22","author":"Medina-Leyte","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacc.2025.08.100_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136822","article-title":"Dysregulated hepatic methionine metabolism drives homocysteine elevation in diet-induced nonalcoholic fatty liver disease","volume":"10","author":"Pacana","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2025.08.100_bib41","doi-asserted-by":"crossref","first-page":"21202","DOI":"10.3390\/ijms151121202","article-title":"Plasma levels of homocysteine and cysteine increased in pediatric NAFLD and strongly correlated with severity of liver damage","volume":"15","author":"Pastore","year":"2014","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacc.2025.08.100_bib42","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/hep.22037","article-title":"The methionine connection: homocysteine and hydrogen sulfide exert opposite effects on hepatic microcirculation in rats","volume":"47","author":"Distrutti","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2025.08.100_bib43","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.3390\/cells11233843","article-title":"The role of oxidative stress in atherosclerosis","volume":"11","author":"Batty","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jacc.2025.08.100_bib44","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1253\/circj.CJ-08-1169","article-title":"Endothelial dysfunction: the first step toward coronary arteriosclerosis","volume":"73","author":"Vanhoutte","year":"2009","journal-title":"Circ J"},{"key":"10.1016\/j.jacc.2025.08.100_bib45","doi-asserted-by":"crossref","first-page":"4411","DOI":"10.3390\/ijms20184411","article-title":"Vascular endothelial cell biology: an update","volume":"20","author":"Kr\u00fcger-Genge","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacc.2025.08.100_bib46","doi-asserted-by":"crossref","first-page":"443","DOI":"10.4254\/wjh.v7.i3.443","article-title":"Endothelial dysfunction in cirrhosis: role of inflammation and oxidative stress","volume":"7","author":"Vairappan","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jacc.2025.08.100_bib47","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2174\/1573403X16666200618161942","article-title":"Endothelial dysfunction and coronary vasoreactivity - a review of the history, physiology, diagnostic techniques, and clinical relevance","volume":"17","author":"Gunawardena","year":"2021","journal-title":"Curr Cardiol Rev"},{"key":"10.1016\/j.jacc.2025.08.100_bib48","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/hep.23719","article-title":"Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites","volume":"52","author":"Neuschwander-Tetri","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2025.08.100_bib49","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1053\/j.gastro.2012.02.003","article-title":"Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications","volume":"142","author":"Cusi","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jacc.2025.08.100_bib50","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3390\/nu15040921","article-title":"A glimpse into milestones of insulin resistance and an updated review of its management","volume":"15","author":"Aedh","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.jacc.2025.08.100_bib51","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.2147\/DMSO.S250699","article-title":"Anti-lipolysis induced by insulin in diverse pathophysiologic conditions of adipose tissue","volume":"13","author":"Zhao","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.jacc.2025.08.100_bib52","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.3748\/wjg.v29.i25.3999","article-title":"Insulin resistance and adipose tissue interactions as the cornerstone of metabolic (dysfunction)-associated fatty liver disease pathogenesis","volume":"29","author":"Pal","year":"2023","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jacc.2025.08.100_bib53","doi-asserted-by":"crossref","DOI":"10.1177\/03000605231164548","article-title":"Insulin resistance and cardiovascular disease","volume":"51","author":"Kosmas","year":"2023","journal-title":"J Int Med Res"},{"key":"10.1016\/j.jacc.2025.08.100_bib54","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.3390\/ijms22084156","article-title":"Role of insulin resistance in MAFLD","volume":"22","author":"Sakurai","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacc.2025.08.100_bib55","doi-asserted-by":"crossref","first-page":"9646","DOI":"10.3390\/ijms21249646","article-title":"Nonalcoholic fatty liver disease and non-alcoholic steatohepatitis: current issues and future perspectives in preclinical and clinical research","volume":"21","author":"Berardo","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacc.2025.08.100_bib56","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1161\/ATVBAHA.114.303035","article-title":"Links between ectopic fat and vascular disease in humans","volume":"34","author":"Lim","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2025.08.100_bib57","article-title":"Impact of dysfunctional adipose tissue depots on the cardiovascular system","volume":"23","author":"D'Oria","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacc.2025.08.100_bib58","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1080\/10408398.2021.1966738","article-title":"Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut-liver axis","volume":"63","author":"Han","year":"2023","journal-title":"Crit Rev Food Sci Nutr"},{"key":"10.1016\/j.jacc.2025.08.100_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1085041","article-title":"The gut microbial metabolite trimethylamine N-oxide and cardiovascular diseases","volume":"14","author":"Zhen","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jacc.2025.08.100_bib60","doi-asserted-by":"crossref","first-page":"5806","DOI":"10.3390\/ijms24065806","article-title":"Modulation of endothelial function by TMAO, a gut microbiota-derived metabolite","volume":"24","author":"Querio","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacc.2025.08.100_bib61","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1080\/14728222.2021.2018418","article-title":"PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date","volume":"25","author":"Cherubini","year":"2021","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.jacc.2025.08.100_bib62","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1194\/jlr.M048777","article-title":"The rs738409 (I148M) variant of the PNPLA3 gene and cirrhosis: a meta-analysis","volume":"56","author":"Shen","year":"2015","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacc.2025.08.100_bib63","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.1210\/clinem\/dgaa729","article-title":"The PNPLA3-I148M variant confers an antiatherogenic lipid profile in insulin-resistant patients","volume":"106","author":"Luukkonen","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2025.08.100_bib64","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.3390\/biomedicines11102809","article-title":"Gene variants implicated in steatotic liver disease: opportunities for diagnostics and therapeutics","volume":"11","author":"Huang","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.jacc.2025.08.100_bib65","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/hep.27490","article-title":"Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease","volume":"61","author":"Dongiovanni","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2025.08.100_bib66","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0025-7125(16)30638-1","article-title":"Drug-induced liver disease","volume":"73","author":"Lewis","year":"1989","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.jacc.2025.08.100_bib67","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/1756283X11430859","article-title":"Secondary causes of nonalcoholic fatty liver disease","volume":"5","author":"Kneeman","year":"2012","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.jacc.2025.08.100_bib68","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1042\/BJ20081916","article-title":"Viral hepatitis and fatty liver disease: how an unwelcome guest makes p\u00e2t\u00e9 of the host","volume":"416","author":"Brown","year":"2008","journal-title":"Biochem J"},{"key":"10.1016\/j.jacc.2025.08.100_bib69","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10534-011-9430-9","article-title":"Systems biology approach to Wilson's disease","volume":"24","author":"Burkhead","year":"2011","journal-title":"Biometals"},{"key":"10.1016\/j.jacc.2025.08.100_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2021.166142","article-title":"Iron depletion attenuates steatosis in a mouse model of non-alcoholic fatty liver disease: role of iron-dependent pathways","volume":"1867","author":"Crawford","year":"2021","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"3","key":"10.1016\/j.jacc.2025.08.100_bib71","first-page":"213","article-title":"Iron perturbations in human non-alcoholic fatty liver disease (NAFLD): clinical relevance and molecular mechanisms","volume":"8","author":"Aigner","year":"2008","journal-title":"Hepatitis Monthly"},{"key":"10.1016\/j.jacc.2025.08.100_bib72","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.mpdhp.2008.09.005","article-title":"Pathology of fatty liver: differential diagnosis of non-alcoholic fatty liver disease","volume":"14","author":"Yeh","year":"2008","journal-title":"DiagnostiC histopathology"},{"key":"10.1016\/j.jacc.2025.08.100_bib73","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1161\/ATVBAHA.122.318661","article-title":"Comparative associations of nonalcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease with coronary artery calcification: a cross-sectional and longitudinal cohort study","volume":"43","author":"Sung","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2025.08.100_bib74","doi-asserted-by":"crossref","DOI":"10.1177\/20406223221122478","article-title":"Association of NAFLD with cardiovascular disease and all-cause mortality: a large-scale prospective cohort study based on UK Biobank","volume":"13","author":"Ma","year":"2022","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.jacc.2025.08.100_bib75","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/hep.32519","article-title":"Risk of cardiovascular disease and loss in life expectancy in NAFLD","volume":"76","author":"Shang","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2025.08.100_bib76","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","article-title":"Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis","volume":"6","author":"Mantovani","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jacc.2025.08.100_bib77","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cgh.2019.05.004","article-title":"Alcoholic and nonalcoholic fatty liver disease and incident hospitalization for liver and cardiovascular diseases","volume":"18","author":"Chang","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jacc.2025.08.100_bib78","article-title":"Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults","volume":"367","author":"Alexander","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2025.08.100_bib79","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.14309\/ajg.0000000000000401","article-title":"Women with nonalcoholic fatty liver disease lose protection against cardiovascular disease: a longitudinal cohort study","volume":"114","author":"Allen","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jacc.2025.08.100_bib80","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.cgh.2017.11.026","article-title":"Nonalcoholic fatty liver disease associates with increased overall mortality and death from cancer, cardiovascular disease, and liver disease in women but not men","volume":"16","author":"Hwang","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jacc.2025.08.100_bib81","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/imj.13549","article-title":"Association between non-alcoholic fatty liver disease and peripheral artery disease in patients with type 2 diabetes","volume":"47","author":"Zou","year":"2017","journal-title":"Intern Med J"},{"key":"10.1016\/j.jacc.2025.08.100_bib82","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2016.06.001","article-title":"Persistent nonalcoholic fatty liver disease increases risk for carotid atherosclerosis","volume":"151","author":"Sinn","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jacc.2025.08.100_bib83","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d6891","article-title":"Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study","volume":"343","author":"Lazo","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2025.08.100_bib84","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/s12933-023-02070-5","article-title":"Incident cardiac arrhythmias associated with metabolic dysfunction-associated steatotic liver disease: a nationwide histology cohort study","volume":"22","author":"Simon","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2025.08.100_bib85","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1111\/liv.14461","article-title":"Nonalcoholic fatty liver disease is associated with increased risk of atrial fibrillation","volume":"40","author":"Cai","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jacc.2025.08.100_bib86","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/liv.14044","article-title":"Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: an updated meta-analysis","volume":"39","author":"Mantovani","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jacc.2025.08.100_bib87","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.001820","article-title":"Nonalcoholic fatty liver disease is associated with QT prolongation in the general population","volume":"4","author":"Hung","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.08.100_bib88","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s12072-022-10319-6","article-title":"Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis","volume":"16","author":"Yong","year":"2022","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jacc.2025.08.100_bib89","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/hep.27869","article-title":"Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study","volume":"62","author":"VanWagner","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2025.08.100_bib90","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/hepr.12770","article-title":"Effect of non-alcoholic fatty liver disease on left ventricular diastolic function and geometry in the Korean general population","volume":"47","author":"Jung","year":"2017","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jacc.2025.08.100_bib91","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1421642","article-title":"Observational and genetic association of non-alcoholic fatty liver disease and calcific aortic valve disease","volume":"15","author":"Hao","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jacc.2025.08.100_bib92","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.metabol.2015.04.003","article-title":"Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"64","author":"Mantovani","year":"2015","journal-title":"Metabolism"},{"key":"10.1016\/j.jacc.2025.08.100_bib93","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0088371","article-title":"Nonalcoholic fatty liver disease is associated with aortic valve sclerosis in patients with type 2 diabetes mellitus","volume":"9","author":"Bonapace","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2025.08.100_bib94","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/8463640","article-title":"Bidirectional association between hypertension and NAFLD: a systematic review and meta-analysis of observational studies","volume":"2022","author":"Li","year":"2022","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.jacc.2025.08.100_bib95","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/HJH.0000000000001204","article-title":"Gamma-glutamyltransferase, fatty liver index and hepatic insulin resistance are associated with incident hypertension in two longitudinal studies","volume":"35","author":"Bonnet","year":"2017","journal-title":"J Hypertens"},{"key":"10.1016\/j.jacc.2025.08.100_bib96","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1111\/jgh.12643","article-title":"Clinical association between non-alcoholic fatty liver disease and the development of hypertension","volume":"29","author":"Ryoo","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jacc.2025.08.100_bib97","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1097\/HJH.0b013e32833c211b","article-title":"The association between fatty liver disease and blood pressure in a population-based prospective longitudinal study","volume":"28","author":"Lau","year":"2010","journal-title":"J Hypertens"},{"key":"10.1016\/j.jacc.2025.08.100_bib98","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1007\/s00392-023-02250-z","article-title":"Non-alcoholic fatty liver disease (NAFLD) and risk of new-onset heart failure: a retrospective analysis of 173,966 patients","volume":"112","author":"Roderburg","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.jacc.2025.08.100_bib99","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1136\/gutjnl-2021-325724","article-title":"Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort","volume":"71","author":"Simon","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.jacc.2025.08.100_bib100","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021654","article-title":"Nonalcoholic fatty liver disease and risk of heart failure among Medicare beneficiaries","volume":"10","author":"Fudim","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.08.100_bib101","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s12872-020-01444-x","article-title":"Higher fatty liver index is associated with increased risk of new onset heart failure in healthy adults: a nationwide population-based study in Korea","volume":"20","author":"Roh","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jacc.2025.08.100_bib102","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1001\/jama.2023.25115","article-title":"What to know about PREVENT, the AHA's new cardiovascular disease risk calculator","volume":"331","author":"Larkin","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.08.100_bib103","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1161\/CIRCULATIONAHA.124.070535","article-title":"Cardiovascular-liver-metabolic health: recommendations in screening, diagnosis, and management of metabolic dysfunction-associated steatotic liver disease in cardiovascular disease via modified Delphi approach","volume":"151","author":"Chew","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.08.100_bib104","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000055","article-title":"Increased accuracy in identifying NAFLD with advanced fibrosis and cirrhosis: independent validation of the Agile 3+ and 4 scores","volume":"7","author":"Noureddin","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jacc.2025.08.100_bib105","doi-asserted-by":"crossref","first-page":"8508","DOI":"10.1002\/jcp.26791","article-title":"Serum C-reactive protein in the prediction of cardiovascular diseases: overview of the latest clinical studies and public health practice","volume":"233","author":"Avan","year":"2018","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.jacc.2025.08.100_bib106","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000034934","article-title":"Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in a middle-aged population with overweight and normal liver enzymes, and diagnostic accuracy of noninvasive proxies","volume":"103","author":"van Son","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jacc.2025.08.100_bib107","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1210\/jc.2015-1966","article-title":"High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels","volume":"100","author":"Portillo-Sanchez","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2025.08.100_bib108","doi-asserted-by":"crossref","first-page":"530","DOI":"10.4254\/wjh.v10.i8.530","article-title":"Current status of imaging in nonalcoholic fatty liver disease","volume":"10","author":"Li","year":"2018","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jacc.2025.08.100_bib109","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.7150\/thno.40249","article-title":"Quantitative ultrasound approaches for diagnosis and monitoring hepatic steatosis in nonalcoholic fatty liver disease","volume":"10","author":"Pirmoazen","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.jacc.2025.08.100_bib110","doi-asserted-by":"crossref","first-page":"9189","DOI":"10.1038\/s41598-018-27560-5","article-title":"Multiparametric magnetic resonance imaging for quantitation of liver disease: a two-centre cross-sectional observational study","volume":"8","author":"McDonald","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacc.2025.08.100_bib111","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1159\/000539371","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"17","year":"2024","journal-title":"Obes Facts"},{"key":"10.1016\/j.jacc.2025.08.100_bib112","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"issue":"11","key":"10.1016\/j.jacc.2025.08.100_bib113","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.3390\/diagnostics14111083","article-title":"Assessing the utility of acoustic radiation force impulse in the evaluation of non-alcoholic fatty liver disease with severe obesity or steatosis","volume":"14","author":"Kang","year":"2024","journal-title":"Diagnostics"},{"key":"10.1016\/j.jacc.2025.08.100_bib114","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jacc.2025.08.100_bib115","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jacc.2025.08.100_bib116","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/00325481.2024.2325332","article-title":"Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting","volume":"136","author":"Allen","year":"2024","journal-title":"Postgrad Med"},{"key":"10.1016\/j.jacc.2025.08.100_bib117","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/hep.29113","article-title":"Liver fibrosis scores predict liver disease mortality in the United States population","volume":"66","author":"Unalp-Arida","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2025.08.100_bib118","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/liv.14669","article-title":"Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: a systematic review","volume":"41","author":"Lee","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jacc.2025.08.100_bib119","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1053\/j.gastro.2022.06.023","article-title":"AGA clinical practice update: diagnosis and management of nonalcoholic fatty liver disease in lean individuals: expert review","volume":"163","author":"Long","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jacc.2025.08.100_bib120","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2025.08.100_bib121","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update","volume":"75","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jacc.2025.08.100_bib122","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a confounding factor for the accurate noninvasive diagnosis of advanced NAFLD fibrosis","volume":"112","author":"McPherson","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jacc.2025.08.100_bib123","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000443344","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"9","year":"2016","journal-title":"Obes Facts"},{"key":"10.1016\/j.jacc.2025.08.100_bib124","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S2213-8587(18)30154-2","article-title":"Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies","volume":"7","author":"Stefan","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2025.08.100_bib125","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1007\/s10620-007-0074-0","article-title":"Independent predictors of steatohepatitis and fibrosis in Asian Indian patients with non-alcoholic steatohepatitis","volume":"53","author":"Singh","year":"2008","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jacc.2025.08.100_bib126","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.23276","article-title":"Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis","volume":"51","author":"Promrat","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2025.08.100_bib127","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/hep.32274","article-title":"NASHFit: a randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH","volume":"76","author":"Stine","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2025.08.100_bib128","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1001\/jamainternmed.2016.3202","article-title":"Effects of moderate and vigorous exercise on nonalcoholic fatty liver disease: a randomized clinical trial","volume":"176","author":"Zhang","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacc.2025.08.100_bib129","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/hep.26393","article-title":"Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 Randomized Trial)","volume":"58","author":"Bacchi","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2025.08.100_bib130","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1089\/met.2019.0115","article-title":"High-risk atherosclerosis and metabolic phenotype: the roles of ectopic adiposity, atherogenic dyslipidemia, and inflammation","volume":"18","author":"Lechner","year":"2020","journal-title":"Metab Syndr Relat Disord"},{"key":"10.1016\/j.jacc.2025.08.100_bib131","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41569-018-0065-1","article-title":"Exercise benefits in cardiovascular disease: beyond attenuation of traditional risk factors","volume":"15","author":"Fiuza-Luces","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2025.08.100_bib132","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1161\/CIRCULATIONAHA.117.030501","article-title":"Effect of distinct lifestyle interventions on mobilization of fat storage pools: CENTRAL magnetic resonance imaging randomized controlled trial","volume":"137","author":"Gepner","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.08.100_bib133","article-title":"High-intensity aerobic exercise improves both hepatic fat content and stiffness in sedentary obese men with nonalcoholic fatty liver disease","volume":"7","author":"Oh","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacc.2025.08.100_bib134","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jhep.2016.05.026","article-title":"Effect of exercise on the development of new fatty liver and the resolution of existing fatty liver","volume":"65","author":"Sung","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jacc.2025.08.100_bib135","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1001\/jama.2018.14854","article-title":"The physical activity guidelines for Americans","volume":"320","author":"Piercy","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.08.100_bib136","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.jacc.2018.08.2141","article-title":"Promoting physical activity and exercise: JACC Health Promotion Series","volume":"72","author":"Fletcher","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.08.100_bib137","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3390\/jcm10030467","article-title":"NAFLD and cardiovascular diseases: epidemiological, mechanistic and therapeutic considerations","volume":"10","author":"Niederseer","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacc.2025.08.100_bib138","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.cld.2013.09.009","article-title":"The role of diet and nutritional intervention for the management of patients with NAFLD","volume":"18","author":"Barrera","year":"2014","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jacc.2025.08.100_bib139","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/ajg.2012.20","article-title":"What should we recommend to our patients with NAFLD regarding alcohol use?","volume":"107","author":"Liangpunsakul","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jacc.2025.08.100_bib140","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.23527","article-title":"The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis","volume":"51","author":"Ascha","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2025.08.100_bib141","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jhep.2024.06.036","article-title":"Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease","volume":"81","author":"Marti-Aguado","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jacc.2025.08.100_bib142","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1111\/liv.15930","article-title":"The first MASH drug therapy on the horizon: current perspectives of resmetirom","volume":"44","author":"Petta","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.jacc.2025.08.100_bib143","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.100_bib144","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.dld.2014.07.170","article-title":"The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease","volume":"47","author":"Pastori","year":"2015","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jacc.2025.08.100_bib145","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","article-title":"Pleiotropic effects of statins on the cardiovascular system","volume":"120","author":"Oesterle","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2025.08.100_bib146","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1136\/gutjnl-2024-333074","article-title":"Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease","volume":"73","author":"Zhou","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.jacc.2025.08.100_bib147","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2024-001404","article-title":"Statin prescriptions and progression of advanced fibrosis risk in primary care patients with MASLD","volume":"11","author":"Schreiner","year":"2024","journal-title":"BMJ Open Gastroenterol"},{"key":"10.1016\/j.jacc.2025.08.100_bib148","doi-asserted-by":"crossref","DOI":"10.5493\/wjem.v14.i4.98543","article-title":"Statins decrease the risk of hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis","volume":"14","author":"Tarar","year":"2024","journal-title":"World J Exp Med"},{"key":"10.1016\/j.jacc.2025.08.100_bib149","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104392","article-title":"Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study","volume":"87","author":"Ayada","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jacc.2025.08.100_bib150","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.08.100_bib151","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1567-5688(15)50007-X","article-title":"The effect of ezetimibe on NAFLD","volume":"17","author":"Averna","year":"2015","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.jacc.2025.08.100_bib152","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.08.100_bib153","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1007\/s00125-013-3149-9","article-title":"The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial","volume":"57","author":"Takeshita","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacc.2025.08.100_bib154","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/hep.27647","article-title":"Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)","volume":"61","author":"Loomba","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2025.08.100_bib155","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.2174\/1381612824666181010123127","article-title":"The role of PCSK9 in the pathogenesis of non-alcoholic fatty liver disease and the effect of PCSK9 inhibitors","volume":"24","author":"Theocharidou","year":"2018","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jacc.2025.08.100_bib156","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.4254\/wjh.v12.i12.1258","article-title":"Effects of proprotein convertase subtilisin\/kexin type-9 inhibitors on fatty liver","volume":"12","author":"Shafiq","year":"2020","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jacc.2025.08.100_bib157","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.100_bib158","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.100_bib159","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/apt.15316","article-title":"Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and\/or obesity","volume":"50","author":"Newsome","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jacc.2025.08.100_bib160","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.08.100_bib161","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.100_bib162","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.100_bib163","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.100_bib164","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2025.08.100_bib165","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1016\/j.jacc.2018.03.509","article-title":"Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium","volume":"71","author":"Packer","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.08.100_bib166","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamainternmed.2023.8029","article-title":"Outcomes of various classes of oral antidiabetic drugs on nonalcoholic fatty liver disease","volume":"184","author":"Jang","year":"2024","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacc.2025.08.100_bib167","article-title":"Renin-angiotensin-aldosterone system inhibitor use improves clinical outcomes in patients with metabolic dysfunction-associated steatotic liver diseases: target trial emulation using real-world data","author":"Ng","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2025.08.100_bib168","doi-asserted-by":"crossref","first-page":"24155","DOI":"10.18632\/oncotarget.23816","article-title":"Clinical application of angiotensin receptor blockers in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"9","author":"Li","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jacc.2025.08.100_bib169","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1016\/j.cgh.2019.04.061","article-title":"Daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease","volume":"17","author":"Simon","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jacc.2025.08.100_bib170","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1001\/jama.2024.1215","article-title":"Aspirin for metabolic dysfunction-associated steatotic liver disease without cirrhosis: a randomized clinical trial","volume":"331","author":"Simon","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.08.100_bib171","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4254\/wjh.v11.i2.138","article-title":"Bariatric surgery in patients with non-alcoholic fatty liver disease\u2014from pathophysiology to clinical effects","volume":"11","author":"Laursen","year":"2019","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jacc.2025.08.100_bib172","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.soard.2017.09.005","article-title":"Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients","volume":"14","author":"Garg","year":"2018","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.jacc.2025.08.100_bib173","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1001\/jama.2021.19569","article-title":"Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis","volume":"326","author":"Aminian","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.08.100_bib174","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1016\/S0140-6736(23)00634-7","article-title":"Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial","volume":"401","author":"Verrastro","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.08.100_bib175","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jacc.2025.08.100_bib176","article-title":"Integrating the care of metabolic dysfunction-associated steatotic liver disease into cardiac rehabilitation: a multisystem approach","author":"Sebastiani","year":"2025","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacc.2025.08.100_bib177","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1136\/flgastro-2018-101155","article-title":"A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health","volume":"10","author":"Moolla","year":"2019","journal-title":"Frontline Gastroenterol"},{"key":"10.1016\/j.jacc.2025.08.100_bib178","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/hep.31425","article-title":"Modeling the hepatology workforce in the United States: a predicted critical shortage","volume":"72","author":"Russo","year":"2020","journal-title":"Hepatology"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725093726?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725093726?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:44:23Z","timestamp":1773276263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109725093726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":178,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0735109725093726"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2025.08.100","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Basics of Metabolic Dysfunction\u2013Associated Steatotic Liver Disease for Cardiologists","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2025.08.100","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}